Renhe Pharmacy Co.,Ltd (SHE:000650)
5.30
+0.17 (3.31%)
Jun 12, 2026, 3:04 PM CST
Renhe Pharmacy Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,594 | 3,451 | 3,995 | 4,927 | 5,075 | 4,841 |
Other Revenue | 85.52 | 85.52 | 79.63 | 105.17 | 78.56 | 94.45 |
| 3,680 | 3,536 | 4,075 | 5,032 | 5,153 | 4,936 | |
Revenue Growth (YoY) | -3.74% | -13.21% | -19.02% | -2.35% | 4.41% | 15.38% |
Cost of Revenue | 2,335 | 2,243 | 2,542 | 3,187 | 3,308 | 3,071 |
Gross Profit | 1,345 | 1,294 | 1,533 | 1,845 | 1,845 | 1,865 |
Selling, General & Admin | 579.57 | 597.75 | 748.38 | 804.72 | 864.65 | 850.05 |
Research & Development | 44.39 | 45.07 | 43.85 | 46.36 | 50.54 | 52.14 |
Other Operating Expenses | 97.3 | 33.54 | 40.84 | 46 | 44.46 | 37.76 |
Operating Expenses | 753.86 | 708.89 | 861.67 | 901 | 966.32 | 942.38 |
Operating Income | 591.09 | 584.79 | 671.27 | 943.83 | 878.95 | 922.49 |
Interest Expense | -0.08 | -0.09 | -0.17 | -0.35 | -0.43 | -0.98 |
Interest & Investment Income | 76.33 | 86.13 | 86.33 | 87.92 | 70.49 | 88.18 |
Currency Exchange Gain (Loss) | -0 | -0 | - | - | -0 | -0 |
Other Non Operating Income (Expenses) | -2.39 | -3 | -3.15 | -3.39 | -0.69 | -2.01 |
EBT Excluding Unusual Items | 664.94 | 667.83 | 754.29 | 1,028 | 948.33 | 1,008 |
Impairment of Goodwill | -111.01 | -111.01 | -45 | -31.33 | -27.89 | - |
Gain (Loss) on Sale of Investments | 22.71 | 25.12 | 16.03 | 16.83 | 22.11 | -0.03 |
Gain (Loss) on Sale of Assets | 2.06 | 2.05 | 1.37 | -0.27 | 0.34 | 16.84 |
Asset Writedown | -8.56 | -8.51 | -60.01 | -176.3 | -4.53 | -1.44 |
Legal Settlements | -3.3 | -3.3 | -2.3 | - | - | - |
Other Unusual Items | 92.59 | 92.73 | 110.24 | 61.91 | 15.18 | 11.37 |
Pretax Income | 659.43 | 664.9 | 774.62 | 898.86 | 953.54 | 1,034 |
Income Tax Expense | 190.28 | 177.24 | 208.03 | 269.45 | 242 | 234.54 |
Earnings From Continuing Operations | 469.15 | 487.66 | 566.59 | 629.41 | 711.54 | 799.87 |
Minority Interest in Earnings | -99.88 | -94.45 | -84.67 | -62.15 | -137.11 | -134.85 |
Net Income | 369.28 | 393.21 | 481.91 | 567.26 | 574.43 | 665.02 |
Net Income to Common | 369.28 | 393.21 | 481.91 | 567.26 | 574.43 | 665.02 |
Net Income Growth | -21.25% | -18.41% | -15.04% | -1.25% | -13.62% | 14.62% |
Shares Outstanding (Basic) | 1,404 | 1,404 | 1,377 | 1,384 | 1,401 | 1,385 |
Shares Outstanding (Diluted) | 1,404 | 1,404 | 1,395 | 1,400 | 1,401 | 1,385 |
Shares Change (YoY) | 0.67% | 0.65% | -0.34% | -0.08% | 1.13% | 9.85% |
EPS (Basic) | 0.26 | 0.28 | 0.35 | 0.41 | 0.41 | 0.48 |
EPS (Diluted) | 0.26 | 0.28 | 0.35 | 0.41 | 0.41 | 0.48 |
EPS Growth | -21.77% | -18.93% | -14.76% | -1.17% | -14.58% | 4.35% |
Free Cash Flow | 796.56 | 776.72 | 271.54 | 312.92 | 1,049 | 277.93 |
Free Cash Flow Per Share | 0.57 | 0.55 | 0.20 | 0.22 | 0.75 | 0.20 |
Dividend Per Share | 0.150 | 0.150 | 0.150 | 0.200 | 0.200 | 0.100 |
Dividend Growth | - | - | -25.00% | - | 100.00% | -50.00% |
Gross Margin | 36.55% | 36.58% | 37.62% | 36.66% | 35.81% | 37.78% |
Operating Margin | 16.06% | 16.54% | 16.47% | 18.76% | 17.06% | 18.69% |
Profit Margin | 10.04% | 11.12% | 11.83% | 11.27% | 11.15% | 13.47% |
Free Cash Flow Margin | 21.65% | 21.96% | 6.66% | 6.22% | 20.35% | 5.63% |
EBITDA | 705.21 | 699.41 | 787.88 | 1,079 | 990.73 | 1,006 |
EBITDA Margin | 19.16% | 19.78% | 19.34% | 21.44% | 19.23% | 20.37% |
D&A For EBITDA | 114.12 | 114.62 | 116.61 | 134.89 | 111.78 | 83.15 |
EBIT | 591.09 | 584.79 | 671.27 | 943.83 | 878.95 | 922.49 |
EBIT Margin | 16.06% | 16.54% | 16.47% | 18.76% | 17.06% | 18.69% |
Effective Tax Rate | 28.85% | 26.66% | 26.86% | 29.98% | 25.38% | 22.67% |
Revenue as Reported | 3,680 | 3,536 | 4,075 | 5,032 | 5,153 | 4,936 |
Advertising Expenses | - | 69.27 | 161.72 | 202.54 | 217.09 | 215 |